Global ExpansionThe establishment of a U.S. subsidiary expands Kringle Pharma's global footprint, potentially accelerating development and commercialization in a key market, enhancing long-term growth prospects.

Regulatory AdvantageThe orphan drug designation provides regulatory benefits, including market exclusivity, which can enhance the competitive position and profitability of Kringle Pharma's products.

Debt-Free Balance SheetA debt-free balance sheet reduces financial risk, providing Kringle Pharma with greater flexibility to invest in R&D and strategic initiatives without the burden of interest obligations.

Bears Say

Cash Flow ChallengesPersistent negative cash flow indicates significant cash burn, which may necessitate additional funding and could strain financial resources, impacting long-term sustainability.

Declining EquityThe decline in equity reflects sustained losses, eroding the capital base and potentially limiting the company's ability to invest in growth opportunities without external financing.

Revenue VolatilityVolatile and contracting revenue suggests instability in the business model, which can hinder strategic planning and long-term growth, affecting investor confidence and operational stability.

Kringle Pharma, Inc. News

Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast

An update from Kringle Pharma, Inc. ( ($JP:4884) ) is now available. Kringle Pharma reported net sales of...

8d ago

4884

Kringle Pharma Reports Increased Losses and Decline in Financial Position for FY 2025

The latest announcement is out from Kringle Pharma, Inc. ( ($JP:4884) ). Kringle Pharma, Inc. reported its financial...

3M ago

4884

Kringle Pharma’s Phase 3 Study on KP-100LI: A Potential Game-Changer for Vocal Fold Scar Treatment

Kringle Pharma, Inc. (($JP:4884)) announced an update on their ongoing clinical study. Kringle Pharma, Inc. is conducting a...

4M ago

4884

Kringle Pharma Expands Global Reach with New U.S. Subsidiary

The latest update is out from Kringle Pharma, Inc. ( ($JP:4884) ). Kringle Pharma, Inc. has announced the...

4M ago

4884

Kringle Pharma Reports Decline in Nine-Month Financial Performance

Kringle Pharma, Inc. ( ($JP:4884) ) has issued an announcement. Kringle Pharma, Inc. reported a decline in financial...

6M ago

4884

Kringle Pharma’s KP-100IT Receives U.S. FDA Orphan Drug Designation for Spinal Cord Injury

Kringle Pharma, Inc. ( ($JP:4884) ) just unveiled an announcement. Kringle Pharma, Inc. announced that the U.S. FDA...

8M ago

4884

Kringle Pharma Reports Financial Decline in First Half of 2025

Kringle Pharma, Inc. ( ($JP:4884) ) has shared an update. Kringle Pharma, Inc. reported its financial results for...

9M ago

4884

Kringle Pharma Releases Updated Analyst Report to Enhance Investor Insight

Kringle Pharma, Inc. ( ($JP:4884) ) has shared an update. Kringle Pharma, Inc. has announced the release of...

12M ago

4884

Kringle Pharma Reports Flat Sales and Continued Losses

Kringle Pharma, Inc. ( ($JP:4884) ) just unveiled an update. Kringle Pharma, Inc. reported its financial results for...

12M ago

4884

Kringle Pharma Releases New Analyst Report

Kringle Pharma, Inc. (JP:4884) has released an update. Kringle Pharma, Inc. has released an updated analyst report from...

1y ago

4884

4884 FAQ

What was Kringle Pharma, Inc.’s price range in the past 12 months?

Kringle Pharma, Inc. lowest stock price was ¥368.00 and its highest was ¥1125.00 in the past 12 months.

What is Kringle Pharma, Inc.’s market cap?

Kringle Pharma, Inc.’s market cap is ¥2.88B.

When is Kringle Pharma, Inc.’s upcoming earnings report date?

Kringle Pharma, Inc.’s upcoming earnings report date is May 18, 2026 which is in 90 days.

How were Kringle Pharma, Inc.’s earnings last quarter?

Kringle Pharma, Inc. released its earnings results on Feb 09, 2026. The company reported -¥28.2 earnings per share for the quarter, missing the consensus estimate of N/A by -¥28.2.

Is Kringle Pharma, Inc. overvalued?

According to Wall Street analysts Kringle Pharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kringle Pharma, Inc. pay dividends?

Kringle Pharma, Inc. does not currently pay dividends.

What is Kringle Pharma, Inc.’s EPS estimate?

Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kringle Pharma, Inc. have?

Kringle Pharma, Inc. has 7,349,200 shares outstanding.

What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?

Kringle Pharma, Inc. reported an EPS of -¥28.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.806%.

Which hedge fund is a major shareholder of Kringle Pharma, Inc.?

Currently, no hedge funds are holding shares in JP:4884

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kringle Pharma, Inc.

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.